Medicine
Lantus Solostar 100 IU/mL injection
Lantus Solostar 100 IU/mL injection is a prescription medicine containing Insulin glargine for subcutaneous use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unused LANTUS in a refrigerator between 36°F and 46°F (2°C and 8°C). Do…
Key facts
- Active ingredient (INN)
- Insulin glargine
- Brand
- Lantus Solostar
- Strength
- 100 IU/mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 5 syringes
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturers
- Sanofi-AventisA-S Medication Solutions
- Origin register
- US FDA, United States
- Storage
- Store unused LANTUS in a refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze. Not in-use (unopened) Not in-use (unopened) In-use (opened) Refrigerated Room Temperature (36°F–46°F [2°C–8°C]) (up to 86°F [30°C]) 10 mL multiple-dose vial Until expiration date 28 days 28 days Refrigerated or room temperature 3 mL single-patient-use SoloStar prefilled pen Until expiration date 28 days 28…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AE04 Insulin glargine
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 September 2009
- Identifiers
- RxCUI 285018, 311041, 847230 +1DailyMed set ID d5e07a0c-7e14-4756-9152-9fea485d654a, 3a97c40f-0c83-42d7-a8ee-484b208db4e3, 632d9f68-f184-43d5-b184-a3af23f12ad9NDC 0088-2219, 50090-4068, 50090-1398Application BLA021081
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 syringe in 1 carton / 3 mL in 1 syringe | 0088-2219-05 | sanofi-aventis | 23 September 2009 |
| 5 syringe in 1 package / 3 mL in 1 syringe | 50090-1398-0 | A-S Medication Solutions | 28 November 2014 |
| 5 syringe in 1 carton / 3 mL in 1 syringe | 50090-4068-0 | A-S Medication Solutions | 17 January 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Insulin glargine 100 IU/mL injection.
- Insulin glargine 100 IU/mL injectionAvailable on request—US FDA8 packs Cold chain
- Lantus 100 IU/mL injectionAvailable on requestSanofi-AventisUS FDA2 packs Cold chain
- Rezvoglar KwikPen 100 IU/mL injectionAvailable on requestEli LillyUS FDA2 packs Cold chain
- Semglee 100 IU/mL injectionAvailable on requestBiocon BiologicsIndiaUS FDA3 packs Cold chain
- BASAGLAR KwikPen 100 IU/mL injectionAvailable on requestEli LillyUS FDA1 pack Cold chain
- Langlara 100 IU/mL injectionAvailable on requestLanexa BiologicsUS FDA1 pack Cold chain
Other strengths and forms of Insulin glargine
Clinical summary
Insulin glargine is an insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. MedsAcross supplies Insulin glargine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin glargineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BASAGLAR KwikPen prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Lantus: European public assessment report (EPAR) · European Medicines Agency
- Toujeo (previously Optisulin): European public assessment report (EPAR) · European Medicines Agency
Need Lantus Solostar 100 IU/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.